Randomized, double‐blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy

Autor:	Don C. Rockey, K. Rajender Reddy, Stephen D. Zucker, Neeral L. Shah, David C. Wolf, Robert S. Rahimi, A. Mendoza, Iryna Klaryts'ka, Dion F. Coakley, Timothy M. McCashland, Larysa Dudar, Charles D. Howell, Galyna Fadieienko, K. Gautham Reddy, O. Khrustalev, Andrey Baranovsky, Vladimir Grinevich, Olga Alexeeva, Marwan Ghabril, Robert O'Shea, Parvez S. Mantry, K. Zhidkov, Priya Grewal, Benedict Maliakkal, T. Zvyagintseva, Masoud Mokhtarani, Christopher B. O'Brien, Bruce F. Scharschmidt, V. Radchenko, B. Berk, A. Frolov, Vasyl Syplyviy, Samuel H. Sigal, Kimberly A Brown, G. Storozhakov, Robert S. Brown, Igor A. Zupanets, Hillel Tobias, Nathan M. Bass, John M. Vierling, Kirti Shetty, Michael R. Lucey, Klara Dickinson, Michael D. Voigt, Nataliya Kharchenko, Vyacheslav Morozov, Steven A. Weinman, Catherine Norris, M. Porayko, Luis A. Balart, Aijaz Ahmed
Rok vydání:	2014
Předmět:	Adult Glycerol Male medicine.medical_specialty Glutamine Population Placebo Phenylbutyrate Gastroenterology Young Adult chemistry.chemical_compound Double-Blind Method Ammonia Internal medicine Urea Humans Hyperammonemia Medicine Glycerol phenylbutyrate education Hepatic encephalopathy Aged education.field_of_study Hepatology business.industry Hazard ratio Liver Failure/Cirrhosis/Portal Hypertension Middle Aged medicine.disease Phenylbutyrates Surgery Rifaximin Treatment Outcome chemistry Hepatic Encephalopathy Female business
Zdroj:	Hepatology (Baltimore, Md.)
ISSN:	1527-3350 0270-9139
Popis:	Glycerol phenylbutyrate (GPB) lowers ammonia by providing an alternate pathway to urea for waste nitrogen excretion in the form of phenylacetyl glutamine, which is excreted in urine. This randomized, double-blind, placebo-controlled phase II trial enrolled 178 patients with cirrhosis, including 59 already taking rifaximin, who had experienced two or more hepatic encephalopathy (HE) events in the previous 6 months. The primary endpoint was the proportion of patients with HE events. Other endpoints included the time to first event, total number of events, HE hospitalizations, symptomatic days, and safety. GPB, at 6 mL orally twice-daily, significantly reduced the proportion of patients who experienced an HE event (21% versus 36%; P = 0.02), time to first event (hazard ratio [HR] = 0.56; P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07e96841c24ef128ff9451efcc0f5987 https://doi.org/10.1002/hep.26611 Zobrazit plný text záznamu Plný text